Sun Pharmaceutical Industries has received board approval for a significant fundraising initiative through non-convertible debentures. According to reports from Business Standard and Rediff Moneynews, the company's board of directors approved a proposal to raise funds of up to ₹10,000 crore through the issuance of non-convertible debentures (NCDs). The decision was formally announced in a regulatory filing on Monday evening, following the board meeting held on October 12. The stock price of the drug company hit an over five-month low of ₹1,733.15, falling 2% on Wednesday's intra-day deals, marking its lowest level since April 28, 2026.
On October 13, Crisil Ratings assigned its 'Crisil AAA/Stable' rating to the proposed non-convertible debentures of Sun Pharma and reaffirmed its 'Crisil AAA/Stable/Crisil A1+' ratings on the existing bank facilities and commercial paper programme. The ratings continue to reflect Sun Pharma's leadership position in the domestic formulations segment and strong presence in the US and other regulated markets with a robust specialty products portfolio. However, the rating agency noted that these strengths are partially offset by exposure to regulatory risk and susceptibility to intense competition and US policy uncertainties. Despite the recent stock decline, Sun Pharma has outperformed the market and remained flat thus far in calendar year 2026, compared to a 14.7% decline in the BSE Sensex.
Sun Pharma's operating performance remained healthy in the first quarter (April to June) of fiscal 2027, with operating income increasing by around 10% year-on-year to ₹15,300 crore, driven by strong growth in the India formulations and global innovative medicines businesses. India formulations sales grew 16% YoY to ₹5,475 crore, while global innovative medicines sales increased 13% to $351 million and constituted around 22% of consolidated sales. However, US formulations sales declined 10% amid continued weakness in the generics business. Operating profit increased 2.7% to ₹4,418 crore, though operating margin moderated to 29% from 31.1% in the corresponding period of the previous fiscal.
The approved fundraising structure involves the issuance of listed, rated, unsecured, redeemable NCDs on a private placement basis. As reported by Business Standard and Rediff Moneynews, the board approved the issuance of these NCDs in one or more tranches and/or series for an aggregate amount not exceeding ₹10,000 crore. The company has indicated that disclosures required under Regulation 30 of the Sebi (Listing Obligations and Disclosure Requirements) Regulations, 2015, will be made at an appropriate stage upon the issuance or allotment of the debentures.
Sun Pharma faces intense competition in the US generics market with the introduction of authorized generics, customer consolidation, faster pace of ANDA approvals by the US FDA, and healthcare cost-containment measures by the US government. The company's agreement with the US administration provides some mitigation against tariff-related risks for a two-year period, after which the arrangement is subject to review. While Sun Pharma's innovative medicines constitute more than 20% of sales, providing strong momentum, the evolving policy environment in the US, particularly implementation of Most Favoured Nation (MFN)-linked drug pricing measures and tariffs on pharmaceutical products, will remain monitorable factors for the company's future performance.
